# US 2023/0055186 A1 · Engineered immune killer cell, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055186 A1
- Document ID: US20230055186A1
- Status: Published application
- Kind: A1
- Application number: 17/775,812
- Filed: 2020-09-28
- Published: 2023-02-23
- Earliest claimed: 2019-12-27
- Assignees: Zhaotai Immugene Biomedicine (Hong Kong) Limited
- Applicants: Zhaotai Immugene Biomedicine (Hong Kong) Limited
- Inventors: Peng LI; Zhiwu JIANG; Zhaoyang TANG; Le QIN; Rui LIAO; Diwei ZHENG; Yuanbin CUI; Yao YAO; Simiao LIN
- Web page: https://patentgrep.com/patent/US20230055186A1

## CPC

- C12N 15/625: {containing a sequence coding for a signal sequence}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4229: {Transforming growth factor [TGF]}
- A61K 40/4255: {Mesothelin [MSLN]}
- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/53: Liver
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are an engineered immune killer cell, and a preparation method therefor and the use thereof. The engineered immune killer cell is prepared by inducing reprogrammed human T cell, retains the marker and function of the human T cell from which the engineered immune killer cell is derived, has the marker and function of an NK cell, and transfects and expresses, in an obtained immune killer lymphocyte, a CAR molecule which recognizes tumor and virus-associated antigens or a TCR molecule which specifically recognizes a tumor.

## Claims

### Claim 1

An engineered immune killer cell prepared by transfecting a human T cell with a CAR molecule or a TCR molecule targeting a tumor-associated antigen or a virus-associated antigen along with or followed by reprogramming involving deletion or inhibition of a BCL11B gene.

### Claim 2 (depends on 1)

The cell according to claim 1, wherein the immune killer cell expresses the CAR molecule or the TCR molecule targeting the tumor or the virus-associated antigen, retains a marker and a function of the human T cell from which the immune killer cell is derived, and has a marker and a function of NK cells.

### Claim 3 (depends on 1)

The cell according to claim 1, wherein the human T cell is a mature human T cell or a cell population containing mature human T cells;
preferably, the mature human T cell or the cell population containing mature human T cells is derived from cord blood or peripheral blood of a human body;
preferably, the mature human T cell or the cell population containing mature human T cells is derived from a mature T cell or a cell population obtained through differentiation of pluripotent stem cells, embryonic stem cells, or cord blood stem cells.

### Claim 4 (depends on 1)

The cell according claim 1, wherein the immune killer cell expresses functional TCR, CD3, and NKp30.

### Claim 5 (depends on 1)

The cell according to claim 1, wherein the immune killer cell expresses the following marker of NK cells: CD11c, NKG2D, and CD161;
preferably, the immune killer cell performs low expression or no expression of an immunosuppression checkpoint PD-1, CTLA-4, or FOXP3;
preferably, the immune killer cell performs low expression or no expression of an NK-associated marker CD127, CD16, KIRDL2, KIRDL3, NKG2A.

### Claim 6 (depends on 1)

The cell according to claim 1, wherein the immune killer cell upregulates expression of NOTCH compared with the T cell from which the immune killer cell is derived.

### Claim 7 (depends on 1)

The cell according to claim 1, wherein the immune killer cell downregulates expression of transcription factors LEF1 and TCF7 and upregulates expression of NOTCH, AP1, ID2, TBX21, and NFIL3 compared with the T cell from which the immune killer cell is derived.

### Claim 8 (depends on 1)

The cell according to claim 1, wherein TCR-mediated signal transduction of the immune killer cell is enhanced;
preferably, compared with the T cell from which the immune killer cell is derived, the immune killer cell upregulates expression of genes CSF2, FOS, MAPK12, MAP3K8, IFNγ, NFKBIA, MAPK11, IL-10, and TEC which are associated with the TCR-mediated signal transduction;
preferably, compared with NK cells, the immune killer cell has enhanced T cell recognition and TCR signal transduction; preferably, the immune killer cell upregulates expression of CD3, CD4, CD8, and CD40LG.

### Claim 9 (depends on 1)

The cell according to claim 1, wherein compared with the T cell from which the immune killer cell is derived, the immune killer cell has enhanced NK killing toxicity-associated signal transduction;
preferably, compared with the T cell from which the immune killer cell is derived, the immune killer cell upregulates expression of genes PRF1, CSF2, ICAM1, CD244, PLCG2, IFNG, FCER1G, GZMB, NCR2, NCR1, KIR2DL4, and SYK which are associated with the NK killing toxicity-associated signal transduction.

### Claim 10 (depends on 1)

The cell according to claim 1, comprising CD8+NKp46+ NKp44+ NKp30+, CD4+NKp30+, and γδTCR+NKp46+NKp44+NKp30+ T cell subgroups.

### Claim at position 11

-14. (canceled)

### Claim 15 (depends on 1)

The cell according to claim 1, wherein the CAR molecule comprises a signal peptide, an extracellular antigen recognition domain, a transmembrane region, and an intracellular costimulatory domain;
preferably, the CAR molecule comprises the signal peptide, the extracellular antigen recognition domain, the transmembrane region, and the intracellular costimulatory domain in sequence from an N-terminal to a C-terminal.

### Claim 16 (depends on 1)

The cell according to claim 1, wherein the tumor-associated antigen is a tumor surface antigen, a cytokine secreted by a tumor, a surface antigen of a cell associated with immunosuppression of a tumor microenvironment and a cytokine secreted by the cell, or a tumor-associated microbial antigen, preferably the tumor surface antigen, more preferably CD19, GPC3, Mesothelin, PSCA, or MUC1.

### Claim 17 (depends on 1)

A method for preparing the cell according to claim 1, comprising:
(1″) activating a human T cell;
(2″) transfecting the activated human T cell with a CAR molecule expressing a tumor-associated antigen or a tumor-specific TCR molecule along with or followed by performing BCL11B gene knockout; and
(3″) culturing the cell obtained in step (2″) in a T cell culture medium.

### Claim 18 (depends on 17)

The method according to claim 17, wherein in step (1″), the human T cell is a mature human T cell or a cell population containing mature human T cells;
preferably, the mature human T cell or the cell population containing mature human T cells is derived from cord blood or peripheral blood of a human body;
preferably, the mature human T cell or the cell population containing mature human T cells is derived from a mature T cell or a cell population obtained through differentiation of pluripotent stem cells, embryonic stem cells, or cord blood stem cells.

### Claim 19 (depends on 17)

The method according to claim 17, wherein in step (1″),
the human T cell is activated using an anti-human CD3 antibody, an anti-human CD28 antibody, and an anti-human CD2 antibody;
preferably, the T cell is activated through incubation of magnetic beads of the anti-human CD3 antibody, the anti-human CD28 antibody, and the anti-human CD2 antibody mixed with the mature human T cell at a ratio of 1:2.

### Claim 20 (depends on 17)

The method according to claim 17,
wherein in step (2″), the CAR molecule comprises a signal peptide, an extracellular antigen recognition domain, a transmembrane region, and an intracellular costimulatory domain; preferably, the CAR molecule comprises the signal peptide, the extracellular antigen recognition domain, the transmembrane region, and the intracellular costimulatory domain in sequence from an N-terminal to a C-terminal;
preferably, the antigen is the tumor-associated antigen and/or an antigen associated with a microorganism such as a virus or a bacterium;
preferably, the tumor-associated antigen is a tumor surface antigen, a cytokine secreted by a tumor, a surface antigen of a cell associated with immunosuppression of a tumor microenvironment and a cytokine secreted by the cell, or a tumor-associated microbial antigen, preferably the tumor surface antigen, more preferably CD19, GPC3, Mesothelin, PSCA, or MUC1.

### Claim 21 (depends on 17)

The method according to claim 17, wherein in step (2″), the BCL11B gene knockout is performed using CRISPR/CAS9 technology;
preferably, the gene knockout is performed at a second exon of a BCL11B gene;
preferably, the gene knockout is performed at a third exon of the BCL11B gene.

### Claim 22 (depends on 17)

The method according to claim 17, wherein in step (3″), the T cell culture medium comprises IL-2; preferably, the cell obtained in step (2″) is not co-cultured with OP9-DL1.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method for treating a tumor, AIDS and an infectious disease, comprising administering an effective amount of the cell according to claim 1 to subject in need thereof; preferably, the infectious diseases are viral infectious diseases.
